NCT05816759

Evaluate the Pharmacokinetics and Safety Between the Administration of CKD-383 and the Co-administration of CKD-501, D744, and D150

A Randomized, Open-label, Single Oral Dosing, Two-sequence, and Two-period Crossover Study to Evaluate the Pharmacokinetics and Safety Between the Administration of CKD-383 and the Co-administration of CKD-501, D744, and D150 for Healthy Subjects in Fed State

• Status: Completed
• Phase: Phase 1
• Study type: Interventional
• Enrollment: 32 (actual)
• Sponsor: Chong Kun Dang Pharmaceutical · Industry
• Sex: All
• Age: 19 Years – 55 Years
• Healthy volunteers: Accepted

Summary

Evaluate the Pharmacokinetics and Safety Between the Administration of CKD-383 and the Co-administration of CKD-501, D744, and D150 for Healthy Subjects in Fed State

Conditions

• Type 2 Diabetes

Interventions

Type	Name	Description
DRUG	CKD-383	QD, PO
DRUG	CKD-501, D744, D150	QD, PO

Timeline

• Start date: 2023-05-26
• Primary completion: 2023-06-04
• Completion: 2023-06-22
• First posted: 2023-04-18
• Last updated: 2024-01-23

Locations

1 site across 1 country: South Korea